Pyxis Oncology, Inc. PYXS 深 沪
已收盘 07-02 16:00:00 美东时间
2.63
-0.220
-7.72%
华盛通- 最 高3.00
- 今 开2.79
- 成交量 69.45万股
- 最 低 2.63
- 昨 收 2.85
- 总市值 1.67亿
- 52周最高 5.55
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 0.97
- 委 比 -54.66%
- 总股本 6335.55万
- 历史最高 19.00
- 量 比 0.21
- 振 幅 12.98%
- 历史最低 0.8332
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $9 to $7.
07-02 20:34
Pyxis Oncology Commences ~$50M Offering Of 19.6M Common Shares At $2.551/Share
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has entered into definitive securities purchase agreements for a private placement expected to result in gross proceeds of approximately $50 mi...
06-30 19:39
Pyxis Oncology shares are trading lower. The company reported Q1 financial results.
Pyxis Oncology shares are trading lower. The company reported Q1 financial resu...
05-15 03:49
Pyxis Oncology Q1 EPS $(0.37), Inline
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 5.71 percent decrease over losses of $(0.35) per share from the same period last year.
05-14 19:16
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6
Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperform rating and announces Price Target of $6.
05-05 21:26
Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNSCC Model With maMICVO In Combination With Anti-PD-1 at AACR 2026
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will present new preclinical data highlighting that a mouse
04-18 04:07
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
03-24 19:06
Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.33) by 12.65 percent. This is a 50.85 percent increase over losses of $(0.59) per share from
03-23 19:12
